CTS 2026: What to Expect in Las Vegas - Scorecard - MDSpire

CTS 2026: What to Expect in Las Vegas

Arshad M. Khanani, MD, previews this year’s Clinical Trials at the Summit meeting, highlighting new clinical trial data, expert panels discussing a variety of topics, and a keynote by the former director of the FDA’s ophthalmic devices division.

  • By

  • Arshad M. Khanani, MD, MA, FASRS

  • June 1, 2026

  • 2 min

Share

Clinical Scorecard: CTS 2026: What to Expect in Las Vegas

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationOphthalmic professionals and clinical trialists
Care SettingClinical Trials at the Summit meeting

Key Highlights

  • 139 program participants with approximately 90 presentations
  • First-time results from phase 2 and phase 3 trials
  • Panels on artificial intelligence in retinal clinical trials
  • Keynote lecture by Wiley A. Chambers, MD
  • Annual awards: Summit of Excellence for industry and physician, Ascent to Excellence for an up-and-coming clinical trialist

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified

          Not specified

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            CTS 2026: What to Expect in Las Vegas

            • by Arshad M. Khanani, MD, MA, FASRS

            • June 1, 2026

            Related Content

            FOXC1 Duplications Linked to Early-Onset Glaucoma

            FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.

            Accelerating Peer Learning in Eye Care

            Lumenis launches peer-to-peer learning program aimed at developing practical strategies for modern-day practice

            • May 27, 2026

            • 2 min
            VR Perimetry May Match HVF in Glaucoma

            Virtual reality testing shortened visual field exams and was preferred among most patients in a retrospective study.